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Abstract 
 
Background: Mastocytosis are a group of diseases characterized by an accumulation 
of aberrant Mast Cells. Nonsteroidal antiinflammatory drugs are frequently avoided in 
mastocytosis patients, due to concerns about the safety of these drugs in these 
diseases, as they may elicit mast cell mediated symptoms. In the general population, 
hypersensitivity reactions to nonsteroidal antiinflammatory drugs are thought to derive 
from the depletion of Prostaglandin E2 and resulting Leukotriene release. 
Objectives: To determine the prevalence of mediator release symptoms triggered by 
nonsteroidal antiinflammatory drugs in mastocytosis patients, and to assess 
associations with medical findings. 
Methods: Medical records of 417 adults and 137 pediatric were reviewed. Groups 
defined by the tolerance patterns to nonsteroidal antiinflammatory drugs and other 
cyclooxygenase inhibitors were compared for epidemiological, clinical, laboratory and 
imaging variables. 
Results: Tolerance patterns to nonsteroidal antiinflammatory drugs and other 
cyclooxygenase inhibitors were as follows: 79% of the patients tolerated, 5% were 
intolerant, 4% had mast cell-related symptoms elicited by one drug, but tolerated other 
drugs and 3% presented mast cell-related symptoms secondary to one drug and 
avoided others. In the adult sample, intolerance was found to be more frequent in 
patients with aggressive systemic mastocytosis (p=0.019), flushing (p=0.003), pruritus 
(p=0.005), prior anaphylaxis (p=<0.001), multilineage KIT mutation (p=0.002), diffuse 
osteosclerosis (p=<0.001), serum basal tryptase levels above 48 ng/mL (p=0.013), and 
bone marrow burden above 0.012% (p=0.006). Drug challenges were performed in 51 
adult and 21 pediatric patients. Positive challenges were reported in 3 adults, and no 
children.   
Conclusions: In mastocytosis, the frequency of allergic/pseudoallergic reactions to 
cyclooxygenase inhibitors seems to be higher than in the general population, albeit 
lower than previously thought. Such reactions may be more frequent in aggressive and 
under progression forms of the disease. Mastocytosis should not be considered as a 
contraindication for the administration of these drugs. Serum basal tryptase levels 
above 48 ng/mL, and bone marrow burden above 0.012% may be surrogate markers 
for cyclooxygenase inhibitor intolerance, in mastocytosis. 
 
Keywords: Mastocytosis, mast cells, mast cell-mediator release-associated 
symptoms, NSAID hypersensitivity, anaphylaxis.  
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Introduction 
 
Mastocytosis encompasses a heterogeneous group of rare diseases 
characterized by an accumulation of aberrant mast cells (MC) in different tissues and 
organs, such as the skin, bone marrow (BM) and gastrointestinal (GI) tract, among 
others (1, 2). These diseases may affect both children and adults, independently of 
gender (1, 2). The prevalence of mastocytosis is estimated to range from 9 to 13 cases 
per 100,000 (3, 4).  
World Health Organization (WHO) defines seven categories of mastocytosis: 
cutaneous mastocytosis (CM, when limited to the skin), extracutaneous mastocytoma, 
indolent systemic mastocytosis with skin lesions (ISMs+), aggressive systemic 
mastocytosis (ASM), SM associated with other clonal hematological non-MC lineage 
diseases (SM-AHNMD), MC leukemia (MCL) and MC sarcoma (5). In addition, two 
other subvariants of indolent forms of the disease have been recognized: well-
differentiated SM (WDSM) (6) and ISMs- (7).  
Patients suffering from mastocytosis may present signs and symptoms 
resulting from release of MC mediators, infiltration of tissues by MC, or both (8). The 
clinical presentation is quite variable and may range from a complete lack of signs and 
symptoms, to recurrent anaphylaxis (9). Activated MC release a myriad of vasoactive, 
proinflammatory, chemotactic and immunomodulatory mediators, both prestored in 
granules and produced de novo (9). Triggers for the activation of MC have been largely 
described in literature, and include Hymenoptera stings, stress, dentition and drugs, 
such as opioids, or nonsteroidal antiinflammatory drugs (NSAIDs) and other COX 
inhibitors (9, 10).  
According to the WHO Collaborating Centre for Drug Statistics Methodology, 
NSAIDs include butylpyrazolidines (e.g. phenylbutazone), acetic acid derivatives and 
related substances (e.g. diclofenac, etodolac, ketorolac, aceclofenac), oxicams (e.g. 
piroxicam, meloxicam), propionic acid derivatives (e.g. ibuprofen, naproxen, 
dexketoprofen), fenamates (e.g. mefenamic acid), coxibs (celecoxib, etoricoxib) and 
others non-otherwise classified (e.g. nimesulide, nabumetone, clonixin lysine). 
Salycilates (e.g. acetylsalicylic acid – ASA -, diflunisal) are included in analgesics and 
antipyretics. This group also includes drugs with a weak COX-inhibitory capacity: 
pyrazolones (metamizole, propyphenazone) and, an anilide derivative, paracetamol 
(11). 
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NSAIDs inhibit the activity of cyclooxygenases (COX) resulting in antipyretic, 
pain control and antiinflammatory effects. As opposed to NSAIDs, paracetamol exerts a 
weak inhibitory effect on COX-1, and is devoid of antiinflammatory effects. Regarding 
its mechanism of action, some authors have recently reported that, in the majority of 
situations, it is mostly a COX-2 inhibitor (12). Moreover, paracetamol may exert its 
analgesic and antipyretic effects by inhibiting the production of PGE2 in central nervous 
system (12).  
In Spain, the prevalence of allergic reactions to NSAIDs ranges from 1% to 
3% in the adult general population (13). However, these reactions are infrequent in the 
pediatric population (14). Differences in the prevalence of reactions reported in different 
studies, both in adult and pediatric populations, result from differences in the diagnostic 
criteria, as they can be based on anamnesis, or on drug challenges (15). Prevalence of 
MC mediator-related symptoms reported in mastocytosis adult patients in association 
with NSAIDs is 14%, being much lower in pediatric mastocytosis (2%) (16). However, 
these drugs represent 8% (17) to 11% (18) of triggers for anaphylaxis, in adults. 
Therefore, the administration of these drugs in mastocytosis patients should be 
cautious, being frequently and strictly avoided in this group of diseases (19). 
Allergic and pseudoallergic reactions to NSAIDs, and other COX inhibitors  
can be elicited by a specific drug, by a specific group or by structurally unrelated drugs 
(20). Pyrazolones are a frequent cause of IgE-mediated hypersensitivity reactions (20). 
The remaining COX inhibitors usually elicit the symptoms through a non-IgE dependent 
mechanism (pseudoallergic reactions). These reactions are most likely associated with 
inhibition of the COX-1 pathway of the arachidonic acid metabolism (14-18), leading to 
depletion of protective PGE2 (21, 22). PGE2  exerts inhibitory effects on IgE-FcɛRI MC 
activation and relaxation effects on bronchial smooth muscle by binding to the E 
prostanoid receptor 2 (EP2) (23).  Moreover, PGE2 release inhibits the expression of 
leukotriene (LT) C4 synthase, thus increasing the production of cysteinyl-leukotrienes 
(24). The release of these mediators causes clinical signs and symptoms that may 
involve the skin (e.g. pruritus, urticaria, exanthema, angioedema, etc), the airway (e.g. 
bronchospasm), or multiple organs, inducing anaphylaxis (21, 25).  
Patients with pseudoallergic reactions to NSAIDs may present with symptoms 
elicited by COX-1 inhibitors, while tolerating weak COX-1 inhibitors (e.g.  paracetamol) 
and COX-2 selective inhibitors, since they induce a less marked decrease of PGE2, 
resulting in a less significant production of leukotrienes (20, 26). In mastocytosis, the 
mechanism for NSAID-related release of MC mediators is not yet clear. However, COX 
inhibition may play a similar role to the one described for the general population.  
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The aim of this study is to determine the prevalence of MC mediator release 
symptoms triggered by NSAIDs in mastocytosis patients and to assess clinical and 
laboratory findings most frequently associated with, or predictive of such reactions.  
 
 
 
Materials and methods 
 
This retrospective study included 417 adults and 137 pediatric mastocytosis 
patients, followed up by the Spanish Network on Mastocytosis (REMA) until October 
2014. Collected variables included:  
1) epidemiological: gender, and age; 
2) clinical: category of mastocytosis; type of skin lesions in children, age at 
disease onset, presence of atopy, food allergy, asthma, rhinoconjunctivitis 
and/or atopic dermatitis; allergy to Hymenoptera venom; basal MC mediator-
related symptoms (pruritus, flushing, gastrointestinal symptoms) and 
anaphylaxis; tolerance to NSAIDs and other COX inhibitors; MC mediator 
symptoms triggered by NSAIDs and other COX inhibitors; 
3) laboratory: serum basal tryptase (sBT), total serum IgE, specific IgE (when 
available), presence of multilineage KIT mutation, BMMC burden;  
4) imaging studies: computed tomography scan, dual energy X-ray absorptiometry, 
skeletal X-ray survey and/or magnetic resonance imaging, for the diagnosis of 
diffuse osteosclerosis. 
  
 Diagnosis of mastocytosis was based on well-established criteria for 
morphology (27), histopathology, immunohistochemistry (28) and flow cytometry 
immunophenotyping (29). Cutaneous mastocytosis was diagnosed in the presence of a 
biopsy-proven mastocytosis in skin, and absence of enough criteria for SM - presence 
of the major criterion, plus one minor criterion, or in the presence of, at least, three 
minor criteria (Table I), as defined by the WHO (5). Patients with cutaneous 
involvement that were not submitted to BM studies were classified as having MIS, 
since the systemic involvement could not be ruled out. SSM was diagnosed in the 
presence of criteria for SM plus two or more “B” findings, in the absence of “C” findings 
(Table II).  ASM was diagnosed in the presence of criteria for SM, plus at least one “C” 
finding, and in the absence of MC leukemia (MCL). MCL was diagnosed in the 
presence of, at least, 20% MC in BM and, at least, 10% MC in peripheral blood. 
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Table I. WHO defined diagnostic criteria for Systemic Mastocytosis (5). 
Major criterion 
 Presence of multifocal dense aggregates of ≥15 MC in BM and/or other extracutaneous 
tissues. 
Minor criteria 
 Identification of morphologically atypical MC in smears or biopsy sections of BM or other 
extracutaneous organs. 
 Aberrant expression of CD25 and/or CD2 by BMMC. 
 Detection of the D816V KIT mutation in BM, blood, or other extracutaneous organs. 
 sBT 20 g/L in the absence of other disorders associated with increased serum 
tryptase. 
MC: Mast cells; BM: bone marrow; sBT: serum basal tryptase 
 
Table II. “B” and “C” findings (5). 
“B” Findings  
 BM biopsy showing >30% infiltration by MC (focal, dense aggregates) and/or serum 
total tryptase level >200 ng/mL. 
 Signs of dysplasia or myeloproliferation, in non-MC lineage(s), but insufficient criteria for 
definitive diagnosis of a hematopoietic neoplasm (AHNMD), with normal or slightly 
abnormal blood counts. 
 Hepatomegaly without impairment of liver function, and/or palpable splenomegaly 
without hypersplenism, and/or lymphadenopathy on palpation or imaging. 
“C” Findings  
 Palpable splenomegaly with hypersplenism. 
 BM dysfunction manifested by one or more cytopenia(s) (ANC <1.0 x109/L, Hgb <10 
g/dL, or platelets <100 x 109/L), but no obvious nonmast cell hematopoietic malignancy. 
 Palpable hepatomegaly with impairment of liver function, ascites, and/or portal 
hypertension. 
 Malabsorption with weight loss due to gastrointestinal mast cell infiltrates. 
 Skeletal involvement with large osteolytic lesions and/or pathological fractures. 
ANC: absolute neutrophil count; Hgb: hemoglobin. 
 
Pediatric mastocytosis skin lesions were classified as previously described in 
the literature: maculopapular (MPCM), plaque type, nodular/mastocytoma (solitary or 
multiple), diffuse (DCM), and telangiectatic cutaneous mastocytosis (red and brown 
telangiectatic macules) (30).  
Age at disease onset was defined either at the moment when skin lesions first 
appeared, age at first anaphylaxis episode, or when B or C findings were confirmed, in 
patients who presented without skin lesions (5). 
 The presence of KIT mutations in highly purified BMMC and other 
hematopoietic lineages was assessed, in order to ascertain the presence of MC 
restricted or multilineage KIT mutation (31).   
 Peripheral blood count and differential, routine biochemistry including serum 
basal tryptase (sBT) (Phadia ImmunoCAP Tryptase System - Phadia, Uppsala, 
Sweden/Thermo FisherScientific Inc.) and total serum IgE (ThermoFisher Scientific and 
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CAP-FEIA system Unicap 100; Phadia, Uppsala, Sweden) were performed at referral 
and during follow-up. Specific IgE antibodies were measured through ImmunoCAP 
(ThermoFisher Scientific and CAP-FEIA system Unicap 100; Phadia, Uppsala, 
Sweden), whenever there was a high suspicion of IgE-mediated symptoms, if a specific 
assay was commercially available. Cutaneous tests (skin prick and intradermal tests) 
were performed using specific triggers (e.g. Hymenoptera venom, foods and drugs). 
Atopy was diagnosed in patients presenting symptoms suggestive of allergic 
inflammation (rhinitis, bronchospasm, food allergy, etc), in the presence of allergen-
specific IgE, or positive cutaneous tests (32).   
  Allergic/pseudoallergic reactions to NSAIDs and other COX inhibitors were 
assessed for each patient. Initial evaluation was based on anamnesis of reactions 
potentially caused by these drugs, considering time relation between the administration 
and the onset of symptoms, severity of symptoms, and later tolerance to the specific 
drug. Skin prick tests were performed if an underlying IgE-mediated mechanism was 
suspected, and drug challenge tests were performed using the potentially-involved 
drug or other COX inhibitor. The latter were carried out having the risk-benefit ratio in 
consideration, and only when patients gave their consent. The elicitor COX inhibitor 
was used when the level of suspicion for causality was low, and if symptoms were mild. 
Other COX inhibitors, most likely to be tolerated, were used when causality was almost 
certain and/or in the presence of moderate to severe symptoms. Patients who had 
symptoms after taking 2 or more, structurally unrelated NSAIDs or COX inhibitors, were 
classified as NSAID intolerants (NSAIDI) – idiosyncratic reactions. Those who revealed 
no symptoms following the administration of NSAIDs/other COX-inhibitors, excluding 
paracetamol, were considered tolerant. Patients who presented with symptoms elicited 
by only one NSAID/COX-inhibitor were further divided into two groups: one including 
those that avoided only that particular drug, or group, and which tolerated other 
NSAIDs after that episode (group 1), and another comprising those who avoided all 
NSAIDs/COX-inhibitor, excluding paracetamol, from that moment on (group 2). Finally, 
patients who avoided NSAIDs, or other COX-inhibitors excluding paracetamol, since 
the onset of mastocytosis were excluded from the statistical analysis. 
 
Statistical analysis 
 
Median and range values were calculated for continuous variables, while 
frequencies were determined for categorical variables. The Kruskall Wallis or Mann-
Whitney U, and 2 or coefficient tests were used to assess the statistical significance of 
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differences between groups, respectively, for continuous and categorical variables. 
Receiver operating characteristic (ROC) curve analysis was used in order to define the 
optimal cut-off values, and predictive values of continuous variables for intolerance to 
NSAIDs/other COX inhibitors. p values <0.05 were considered to be statistically 
significant. Statistical analysis was performed using IBM SPSS for Windows (version 
23.0) and Microsoft Excel 2010. 
 
 
 
Results 
 
Adult patients 
 
A total of 417 adult mastocytosis patients were included, 221 (53%) were 
females and 196 (47%) were males. Median age was 48 years (range: 19 to 85), and 
median age at onset of the disease was 33 years (range: 0 - 82). Ten patients (2%) had 
CM, 27 (7%) had MIS, 207 (50%) had ISMs+, 126 (30%) had ISMs-, 18 (4%) had 
WDSM, 13 (3%) ASM, 2 (1%) MCL and 8 (2%) ISMs+-AHNMD (2 hypereosinophilic 
syndromes with partial deletion of PDGFRα, 3 idiopathic hypereosinophilias, 1 chronic 
lymphoid leukemia, 1 non-Hodgkin B-cell lymphoma, 1 
myeloproliferative/myelodisplastic syndrome). 
Atopy was present in 40% of patients. Prevalences of allergic diseases were 
8% for drug allergy (other than NSAIDs), 14% for food allergy and 20% for 
Hymenoptera venom allergy. Furthermore, rhinoconjunctivitis, asthma and atopic 
dermatitis were found in, respectively, 11%, 6% and 1% of adult patients.  
Regarding basal MC mediator related symptoms, frequencies were: pruritus 
52%, flushing 43%, gastrointestinal symptoms 37%. Furthermore, anaphylaxis 
occurred in 46% of patients. Concerning clinical findings among categories of 
mastocytosis, pruritus and flushing were more frequent in WDSM, with, respectively, 
83% and 67% (p<0.001 and p=0.003), gastrointestinal symptoms in ASM, having 
occurred in 69%, (p=0.005), and anaphylaxis in ISMs-, with 94% (p <0.001).  
Regarding patterns of tolerance to NSAIDs: 329 patients (79%) tolerated 
NSAIDs, and 48 (12%) had reactions. Specifically, 20 (5%) were intolerant to NSAIDs 
(NSAIDI), 15 (4%) patients had MC-related symptoms elicited by one COX inhibitor, but 
tolerated other groups of drugs (group 1) and 13 (3%) patients presented MC-related 
symptoms secondary to one NSAID and avoided others (group 2). The remaining 40 
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patients never took NSAIDs or other COX inhibitors, other than paracetamol. All but 4 
cases in the NSAIDI group, tolerated paracetamol.  
 Table III shows patterns of tolerance to COX inhibitors, according to the 
category of mastocytosis. Table IV shows the frequency of basal MC mediators-related 
symptoms in groups. Interestingly, pruritus, flushing and anaphylaxis were significantly 
more frequent in all groups in which reactions to COX inhibitors occurred.  
 
 
Table III. Categories of adult mastocytosis grouped by the pattern of tolerance to NSAID/COX inhibitor 
drugs. 
  NSAIDI 
(n=20) 
Intolerants to one COX inhibitor NSAID tolerants 
(n=329) 
p value 
Group 1 
(n=15) 
Group 2 
(n=13) 
CM 1 (5%) 0 1 (8%) 8 (2.5%) NS 
MIS 0 1 (7%) 0 23 (7%) NS 
ISMs+ 12 (60%) 4 (27%) 8 (62%) 168 (51%) NS 
ISMs- 4 (20%) 7 (47%) 2 (15%) 101 (31%) NS 
WDSM 0 2 (13%) 1 (8%) 14 (4%) NS 
SSM 0 0 1 (8%) 2 (0.5%) NS 
SM-AHNMD 0 0 0 7 (2.%) NS 
ASM 3 (15%) 1 (7%) 0 6 (2%) 0.019 
Results expressed as number of patients out of total number of patients in the group and percentage 
between brackets. 
ASM: Aggressive Systemic Mastocytosis; CM:Cutaneous Mastocytosis; ISMs+: Indolent Systemic 
Mastocytosis presenting with skin lesions; ISMs-: Indolent Systemic Mastocytosis without skin lesions; 
MIS: Mastocytosis in the Skin; NSAIDI: Nonsteroidal antiinflammatory drugs intolerants; SSM. Smoldering 
Systemic Mastocytosis; SM-AHNMD: Systemic mastocytosis with associated clonal hematological non-
mast cell lineage disease; WDSM: Well-Differentiated Systemic Mastocytosis. 
 
 
 
Table IV. Basal MC mediators related symptoms of adult mastocytosis patients grouped according to the 
pattern of tolerance to COX inhibitors drugs. 
 NSAIDI 
(n=20) 
Intolerants to one COX inhibitor NSAID tolerants 
(n=329) 
p value 
Group 1 
(n=15) 
Group 2 
(n=13) 
Flushing 15 (76%) 7 (46%) 9 (69%) 129 (39%) 0.003 
Pruritus 16 (80%) 11 (73%) 10 (77%) 163 (50%) 0.005 
GI symptoms 8 (40%) 5 (33%) 7 (54%) 117 (36%) NS 
Anaphylaxis 17 (85%) 10 (67%) 10 (83%) 137 (41%) <0.001 
Results expressed as number of patients out of total number of patients in the group and percentage 
between brackets 
NS: not significant; NSAIDI: Intolerants to nonsteroidal antiinflammatory drugs; GI: Gastrointestinal 
 
 
Table V depicts the frequency of each COX inhibitor as elicitor of MC mediator 
related symptoms and Table VI describes the specific MC related symptoms elicited by 
COX inhibitors in every group - no statistically significant differences were found.  
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Table V. Frequencies of NSAIDs and other COX inhibitors as elicitors of MC mediators related symptoms 
in adult mastocytosis grouped by type of tolerance to these drugs. 
 
Drug/group 
NSAIDI 
(n=20) 
 
Intolerants to one COX inhibitor  
Total 
 
Group 1 
(n=15) 
Group 2 
N=13) 
Ibuprofen 13 (65%) 1 (7%) 6 (46%) 20 (42%) 
ASA 11 (55%) 3 (20%) 6 (46%) 20 (42%) 
Metamizole and other pyrazolones 10 (50%) 8 (53%) 1 (8%) 19 (40%) 
Diclofenac 5 (25%) 3 (20%) 0 8 (17%) 
Coxibs 4 (20%) 0 0 4 (8%) 
Paracetamol 4 (20%) 0 0 4 (8%) 
Clonixin 2 (10%) 0 0 2 (4%) 
Dexketoprofen 2 (10%) 0 0 2 (4%) 
Nabumetone 1 (5%) 0 0 1 (2%) 
Naproxen 1 (5%) 0 0 1 (2%) 
Results expressed as number of patients out of total number of patients in the drug/group, and percentage 
between brackets 
NSAIDI: Intolerants to nonsteroidal antiinflammatory drugs; ASA: acetylsalicylic acid 
 
 
 
Table VI. Clinical findings during reactions to NSAIDs and other COX inhibitors in adult patients, according 
to the pattern of intolerance to COX inhibitor drugs. 
 NSAIDI 
(n=20) 
 
Intolerants to one COX inhibitor 
Group 1 
(n=15) 
Group 2 
(n=13) 
Pruritus 5 (25%) 4 (27%) 0 
Hives 5 (25%) 4 (27%) 3 (23%) 
Angioedema 6 (33%) 3 (20%) 3 (23%) 
Conjunctivitis 2 (10%) 0 1 (8%) 
Rhinitis 2 (10%) 0 2 (15%) 
Wheezing 1 (5%) 1 (7%) 1 (8%) 
Dyspnea 7 (35%) 3 (20%) 1 (8%) 
Abdominal cramping 1 (5%) 0 1 (8%) 
Diarrhea 2 (10%) 0 3 (23%) 
Flushing 11 (55%) 6 (40%) 4 (31%) 
Tachycardia 8 (40%) 2 (13%)  4 (31%)  
Presyncope 0  2 (13%) 3 (23%) 
Syncope 6 (33%) 3 (20%) 3 (23%) 
Anaphylaxis 13 (65%) 8 (53%) 10 (77%) 
Results expressed as number of patients out of total number of patients in the group and percentage 
between brackets 
NSAIDI: Intolerants to nonsteroidal antiinflammatory drugs 
 
 
Anaphylaxis caused by NSAID/or other COX inhibitors occurred in 31 (8%) 
patients, among patients who took these drugs, being the cause for 16% of 
anaphylaxis on the total sample. The drug most frequently associated with anaphylaxis 
caused was ASA, as depicted in Table VII. 
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Table VII. Frequencies of NSAIDs and other COX inhibitors as elicitors of anaphylaxis. 
Drug/group Anaphylaxis 
ASA 13 (42%) 
Metamizol and other pyrazolones 11 (35%) 
Ibuprofen 10 (32%)  
Diclofenac 7 (23%) 
Paracetamol 3 (10%) 
Coxibs 2 (6%) 
Clonixin 1 (3%) 
Dexketoprofen 1 (3%) 
Nabumetone 1 (3%) 
Naproxen 0 
Results expressed as number of patients out of total number of patients who had anaphylaxis caused 
caused by NSAID/Cox inhibitors and percentage between brackets 
ASA: acetylsalicylic acid 
 
 
In the NSAIDI group, 1 patient reacted to 5 different COX inhibitors (including 1 
coxib) while tolerating paracetamol, 4 patients reacted to 4 COX inhibitors (including 
coxibs and paracetamol in 3 cases, while 1 case never took paracetamol) and 2 
patients reacted to 3 COX inhibitors (paracetamol was involved in one of them, while 
the other patient tolerated this drug). The remaining 13 cases reacted to 2 NSAIDs, 
and all tolerated paracetamol. 
 Three out of four patients who presented with MC mediators-related symptoms 
induced by paracetamol were females, and all 4 had a prior history of anaphylaxis not 
triggered by COX inhibitors.  
 A total of 51 patients underwent drug challenges with coxibs – celecoxib (n=49) 
and etoricoxib (n=2) -, and meloxicam (n=10). The pattern of tolerance to COX 
inhibitors among them was: NSAIDI in 14 cases, group 1 in 5 patients, group 2 in 7 
cases, NSAID tolerance in 9 patients, and 16 cases never took COX inhibitors, except 
paracetamol. Three NSAIDs patients had a positive challenge, 2 with etoricoxib and 1 
with celecoxib, 2 of which did not tolerate paracetamol. 
Table VIII shows epidemiological, clinical and laboratory characteristics of 
patients grouped by pattern of tolerance to COX inhibitors. The NSAIDI group had 
higher sBT values (p=0.001), percentage of BMMC burden (p=0.013), and frequencies 
of multilineage KIT mutation and diffuse osteosclerosis (p=0.002 and p<0.001, 
respectively). On the other hand, values of total IgE and eosinophils (p=0.02 and 
p=0.01, respectively) were shown to be lower in the NSAIDI group. 
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Table VIII. Epidemiological, clinical and laboratory characteristics of adult mastocytosis patients grouped 
according to the pattern of tolerance to COX inhibitors drugs. 
 
NSAIDI 
(n=20) 
Intolerants to one COX inhibitor NSAID 
tolerants 
(n=329) 
p value 
Group 1 
(n=15) 
Group 2 
(n=13) 
Gender (female) 16 (80%) 9 (60%) 11 (85%) 166 (51%) 0.006 
Median age at 
onset (years) 
32 (8-72) 32 (0-67)  31 (1-59)  34 (0-82)  NS 
Atopy 2 (10%) 6 (40%) 4 (31%) 136 (41%) 0.05 
Rhinoconjunctivitis 0  0   1 (8%) 37 (11%) NS 
Asthma 0 0   3 (23%) 1 (5%) 0.017 
Atopic dermatitis 0 0 0 4 (1%) NS 
Food allergy 2 (10%) 2 (13%) 1 (8%) 45 (14%) NS 
Hymenoptera sting 0  0  2 (15%) 73 (22%) 0.019 
Multilineage  
KIT mutation * 
10 (50%) 1 (7%) 3 (23%) 53 (17%) 0.002 
Diffuse 
osteosclerosis **  
6 (32%) 2 (13%) 0 16 (6%) <0.001 
IgE (kU/L) *** 8.8 (2-37)  38 (4.18-136)  19.5 (2-393)  19.7 (1-2425)  0.019 
Eosinophils 
absolute count †  
0.116 (0.03-
0.2) 
0.2 (0.15-1.1)  0.31 (0.2-0.45) 0.2 (0.04-5.6)  0.01 
sbT (ng/mL) 98.65 (4.92-
877) 
26.5 (4-2222)  35.7 (8.12-164)  23.8 (3.20-
1700)  
0.001 
sbT >48 ng/mL 15 (75%) 4 (27%) 6 (46%) 86 (22%) <0.001 
BMMC  
Burden (%) ‡ 
0.35 (0.002-
22.8) 
0.16 (0.01-7.5)  0.05 (0.006-0.4)  0.09 (0-18) 0.013 
BMMC 
burden  >0.115% 
12 (63%) 7 (54%) 88 (31%) 2 (17%) 0.006 
Categorical variables: Results expressed as number of patients out of total number of patients in the group 
and percentage between brackets; Continuous variables: Results expressed as median in the group and  
range between brackets 
BM: bone marrow; NS: not significant; NSAIDI: Intolerants to nonsteroidal antiinflammatory drugs; 
MC: mast cells; sBT: serum baseline tryptase;      
* Analyzed in 355 patients 
** Analyzed in 337 patients 
*** Collected in 268 patients 
† Collected in 192 patients 
‡ Assessed by flow cytometry, performed in 332 patients 
 
 
 ROC curve analysis showed that levels of sBT≥48 ng/mL (Figure 1) and 
percentage of BMMC burden ≥0.12% (Figure 2) were able to predict intolerance to 
NSAIDs in adult mastocytosis patients, with a sensitivity of 75% and 68%, a specificity 
of 73% and 62%, respectively. AUC for both IgE and eosinophil absolute count was 
found not to be statistically significant. 
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Figure 1. Receiver Operating Characteristics (ROC) curve analysis of serum basal tryptase levels for the 
identification of NSAIDI patients. 
sbT cut-off AUC 95% CI p value Sensitivity Specificity PPV NPV 
48 ng/mL 0.73 0.622-0.882 <0.001 75% 73% 14% 98% 
 
AUC: Area under curve; CI: Confidence interval; NPV: Negative predictive value; NSAIDI: Intolerants to 
nonsteroidal antiinflammatory drugs; PPV: Positive predictive value; sbT: Serum basal tryptase. 
 
 
 
 
 
 
Figure 2. Receiver Operating Characteristics (ROC) curve analysis of BMMC burden for the identification 
of NSAIDI patients. 
BMMC cut-off AUC 95% CI p value Sensitivity Specificity PPV NPV 
0.16%  0.675 0.517-0.832 0.011 68% 62.3% 10% 97% 
 
AUC: Area under curve; CI: Confidence interval; BMMC: Bone marrow mast cell; NPV: Negative predictive 
value; NSAIDI: Intolerants to nonsteroidal antiinflammatory drugs; PPV: Positive predictive value. 
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Interestingly, in the NSAIDI group, the presence of sBT ≥48 ng/mL and BMMC 
burden ≥0.12% were both associated with the presence of multilineage KIT mutation 
(p=0.001 and p=0.002, respectively) and/or diffuse osteosclerosis (p<0.001 and 
p=0.002, respectively). 
 
 
 
Pediatric patients 
 
A total of 137 mastocytosis pediatric patients were included, 67 (49%) of which 
were girls and 70 (51%) were boys, with a median age of 10 years (range: 1 – 17). 
Thirteen (10%) patients had cutaneous mastocytoma (cM), 5 (4%) had WDSM, and the 
remaining 118 (86%) had MIS. Distribution of patterns of skin lesions were as follows: 
87 (64%) patients had a maculopapular (MPCM) form, 19 (14%) had nodules, 10 (7%) 
had plaques (PCM), and 8 (6%) had diffuse cutaneous mastocytosis (DCM). Regarding 
basal MC mediators related symptoms, 68 (50%) children had pruritus, 52 (38%) had 
flushing, and 40 (29%) had GI symptoms. Furthermore, a total of 7 (5%) had prior 
history of anaphylaxis. The median value of sBT was 5.3 ng/mL (range: 1.1-149). 
One hundred and twenty (88%) pediatric mastocytosis patients tolerated 
paracetamol and 50 (36%) patients never received NSAIDs. Eighty-three (61%) 
patients received ibuprofen (among them, 7 and 2 also received metamizole and ASA, 
respectively), 3 (2%) only received metamizole, and the remaining patient (0.7%) only 
received ASA. 
A total of 79 (58%) cases were included in the NSAIDs tolerant group. Seven patients 
were included in group 2 – all reactions were elicited by ibuprofen -, while the 
remaining case was classified as group 1 – the reaction was induced by metamizole.  
Patterns of tolerance to NSAIDs, according to the form of mastocytosis are 
specified in Table IX. Interestingly, statistically significant differences were not found 
among these groups regarding epidemiological, clinical and laboratory characteristics. 
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Table IX. Epidemiological, clinical and laboratory features of pediatric, according to the pattern of tolerance 
to COX inhibitors. 
 Intolerants to one COX inhibitor NSAID tolerants 
n=79 
p value 
Group 1 
n=1 
Group 2 
n=7  
Female (gender) 1 (100%) 4 (57%) 34 (43%) NS 
Median age at onset (Years) 0 0 (0-8) 0 (0-7) NS 
MPCM 1 (100%) 5 (71%) 51 (65%) NS 
Plaque CM 0 0 8 (10%) NS 
Nodular CM 0 0 6 (8%) NS 
cM 0 1 (14%) 9 (11%) NS 
DCM 0 1 (14%) 2 (3%) NS 
WDSM 0 0 3 (4%) NS 
sbT (ng/mL) 9.9 5.7 (1.1-149) 5.6 (1.1-68.7) NS 
Flushing 0 3 (43%) 27 (34%) NS 
Pruritus 1 (100%) 5 (71%) 42 (53%) NS 
GI symptoms 0 2 (29%) 23 (30%)  NS 
Anaphylaxis 0 1 (14%) 3 (4%) NS 
Categorical variables: Results expressed as number of patients out of total number of patients in the group 
and percentage between brackets; Continuous variables: Results expressed as median in the group and 
range between brackets;  
cM: Cutaneous Mastocytoma; CM: Cutaneous Mastocytosis; DCM: Diffuse Cutaneous Mastocytosis; 
WDSM: Well-Differentiated Systemic Mastocytosis; GI: gastrointestinal; NSAIDI: Intolerants to nonsteroidal 
antiinflammatory drugs; sbT: serum basal tryptase. 
 
 
 Drugs challenges were performed in 25 patients. All challenges were negative, 
thus proving absence of intolerance to ibuprofen in 21 cases, metamizole in 2 cases 
and celecoxib in 2 cases. The latter drug was used in 14 and 17 year old patients. 
 
 
 
Discussion 
 
 In this study, we have shown that MC mediator release episodes caused by 
drugs that inhibit the COX occur in 12% and 9% of, respectively, adult and pediatric 
mastocytosis patients that received such drugs. Also, 5% of adults and no pediatric 
patients were shown to be intolerant to NSAIDs. Thus, allergic/pseudoallergic 
symptoms elicited by NSAID are significantly more common in mastocytosis, when 
comparing with the general population. Moreover, the prevalence of such reactions is 
similar to the one found is asthma, which rounds 4% to 11%, but still inferior to the one 
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described in chronic urticaria, which may reach 27% to 35% (33) and MC activation 
plays a key role in both diseases.  
 In mastocytosis the risk of MC mediated symptoms caused by such COX 
inhibitors is not as high as previously thought, notwithstanding the fact that it 
manifested as anaphylaxis, in 8% of adults, which represented 16% of triggers for 
anaphylaxis.  Interestingly, in the adult series, those who presented with symptoms 
derived from MC mediator release had a higher frequency of prior anaphylaxis. This 
finding was particularly more striking in NSAIDI and group 2 patients. Group 2 patients 
had other resemblances with NSAIDI: both displayed a female gender preference, high 
frequencies of flushing and anaphylaxis, and ASA and ibuprofen were the main 
implicated drugs, in both. As such, at least some patients in group 2 may be NSAID 
intolerants. Moreover, prevalence of asthma was higher in group 2, which would be 
more expected in NSAID intolerants, similarly as to what occurs in the general 
population.   
 Adult patients with anaphylaxis caused by Hymenoptera sting are less prone to 
NSAID intolerance. In fact, 97% of patients with Hymenoptera venom allergy tolerated 
NSAIDs. These patients were reported to be mainly male, less symptomatic, and to 
present with lower sbT levels, absence of multilineage KIT mutation, and a low BMMC 
burden (34), opposing features found in adult NSAIDI patients. 
 As occurs in the general population (35), propionic acid derivatives were found 
to be the most frequent elicitors for NSAID MC mediated reactions. This finding may be 
explained by the fact that these are the most frequently prescribed NSAIDs, in all age 
groups (35). In the adult series, they were followed by ASA and pyrazolones. The 
latter, are commonly prescribed in Spain, and are reported to be a frequent cause of 
IgE-mediated reactions to drugs (35). In this study, pyrazolones were the most frequent 
cause for group 1 intolerance, but were also frequently involved in NSAID intolerance 
(idiosyncratic reactions). This finding is unusual since pyrazolones are often considered 
to be weak COX-1 inhibitors (36, 37). Moreover, hypersensitivity to pyrazolones is 
strongly associated with HLA-DQ and HLA-DR expression (33), which has been found 
to occur in ISM, ASM and MCL patients (38). Thus, the mechanism through which 
metamizole and other pyrazolones induce MC mediator release in mastocytosis may 
be complex and multifactorial.   
 Mastocytosis patients were previously reported to be prone to intolerance to 
ASA while being tolerant to NSAIDs (35). In our study, this finding is confirmed in only 
3 patients (20% of group 1). 
 Hypersensitivity reactions to NSAIDs in general population, were reported not to 
be associated with increased sBT levels (39). However, in this study, sBT levels above 
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48 ng/mL and a BMMC burden above 0.12% are proposed as surrogate markers to 
predict intolerance to NSAIDs in mastocytosis patients. Additionally, multilineage KIT 
mutation and diffuse osteosclerosis are more frequent in the NSAIDI group. Higher sBT 
levels, BMMC burden, presence of multilineage KIT mutation and diffuse osteosclerosis 
are associated with progression to aggressive categories of the disease (40, 41). As 
such, the non-indolent forms of mastocytosis may be at superior risk for intolerance to 
NSAIDs, as shown by a significantly higher frequency of intolerance to NSAIDs and 
other COX inhibitors in ASM patients. Moreover, patients with both CM and WDSM, 
presenting without the D816V KIT mutation in the BMMC had a very low frequency of 
intolerance to NSAIDs. These findings may be explained by a lack of upregulation of 
the transcription of genes involved in the arachidonic acid metabolism in MC without 
the D816V mutation, that is present in the MC of ASM and ISM, and absent in CM and 
WDSM (42).    
 In our study, reactions to paracetamol and coxibs were found to be infrequent in 
adult patients, and absent in children. These results are coherent with previous studies 
in non-mastocytosis-related intolerance to NSAIDs (20, 26). Tolerance to paracetamol, 
coxibs and/or to meloxicam was confirmed in the vast majority of intolerant patients. 
However, paracetamol elicited MC mediator release in 20% of NSAID intolerant 
patients. This frequency is superior to the one described in the literature for aspirin-
intolerant asthma patients, rounding 7% (25). Our results show that MC related 
mediator symptoms caused by paracetamol and COX inhibitors only occur in NSAIDI, 
similarly to which occurs in the general population (16).  
 This study has some limitations. As drug challenges were not routinely carried 
out, due to safety concerns or refusal of patients, there is a lack of evidence that the 
drugs in study actually caused MC mediator release mediated symptoms. In fact, drug 
challenges were performed with the purpose of finding safer alternative drugs. Data 
obtained in pediatric patients are less informative, as the sample size was smaller, and 
the administration of NSAIDs was more limited. 
 There is still a high percentage of both adult and pediatric patients that have 
never taken NSAIDs due to fear of serious reactions. This fact has significant 
implications on patients’ quality of life, as the management of pain may become a 
source of anxiety, for both patient and health care professionals. However, our results 
show that NSAIDs do not trigger MC activation in mastocytosis as frequently as widely 
assumed. We recommend that patients who require NSAIDs and who have never 
taken them should be submitted to drug challenges with the drug(s) that offers the 
safest profile, for each case. In our experience, coxibs and meloxicam should be used 
in adults, and ibuprofen in children. Patients which have tolerated specific NSAIDs 
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following the onset of the disease, do not require further testing, and may be instructed 
to take a previously tolerated drug(s) (43).    
 
 
 
Conclusion 
 
 Based on the retrospective analysis of a large series of adults and children with 
mastocytosis, we may conclude that symptoms associated with MC mediator release 
COX inhibitors are more frequent in mastocytosis, than in the general population. No 
clinically dramatic or fatal outcomes have been reported, in this series. As such, 
mastocytosis should not be considered as an absolute contraindication for the 
administration of NSAIDs, or other COX inhibitors. Nevertheless, it is strongly 
recommended that only drugs with the safest profile are used. Drugs to be preferably 
chosen in adults include those previously tolerated by the patient, coxibs, meloxicam 
and paracetamol. In children, ibuprofen may be used. If tolerance to COX inhibitors is 
unknown, a controlled drug challenge is recommended, and the drug should be chosen 
among those mentioned above.  
 Intolerance to NSAIDs was associated with aggressive categories of the 
disease, or with data suggesting possible future progression of the disease 
(multilineage KIT mutation and diffuse osteosclerosis). Hence, in these mastocytosis 
categories, NSAID administration should be cautiously planned, and the drug should 
be chosen carefully.  
 sBT levels above 48 ng/mL, and a BMMC burden above 0.12% emerge as 
potentially useful surrogate markers, as predictors of NSAIDs intolerance in 
mastocytosis. However, further studies are necessary to validate their routine usage. 
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Resumo Circunstanciado 
 
 
 
 
 
 
 
 
Introdução 
 
 As mastocitoses são um grupo de doenças raras, caracterizadas pela 
acumulação de mastócitos anormais, em diferentes tecidos e órgãos (1, 2). Estas 
doenças surgem em indivíduos de todas as idades, sem preferência de género (1, 2). 
Estima-se que a sua prevalência esteja compreendida entre os 9 e os 13 casos por 
cada 100.000 habitantes (3, 4). A sintomatologia das mastocitoses decorre da 
libertação de mediadores mastocitários, da infiltração tecidual, ou de ambos (8). 
Quando ativados, os mastócitos secretam uma miríade de mediadores vasoativos, 
proinflamatórios, quimiotáticos e imunomoduladores (9). Os fatores despoletadores da 
ativação mastocitária incluem picadas por Himenópteros, stress, erupção dentária, e 
fármacos, tais como os opióides e os anti-inflamatórios não esteroides (AINEs) e 
outros inibidores da COX (10).  
De acordo com a classificação ATC (11), os anti-inflamatórios incluem as 
butilpirazolidinas, derivados do ácido acético, derivados do ácido propiónico, 
fenamatos, coxibes e outros. Os fármacos analgésicos e antipiréticos incluem os 
salicilatos e outros, com reduzida capacidade inibitória das COX, tais como o 
paracetamol. 
 Os AINEs inibem a ação das ciclooxigenases (COX). Deste mecanismo de 
ação resultam efeitos antipiréticos, controlo da dor e efeitos anti-inflamatórios. Por sua 
vez, o paracetamol e outros inibidores fracos da COX-1, atuam ao nível do sistema 
nervoso central, exercendo, apenas, efeitos antipiréticos e analgésicos (12). 
 Em Espanha, a prevalência de reações alérgicas a AINEs varia entre 1% e 3%, 
nos adultos, sendo muito pouco frequente nas crianças (13, 14). Nas mastocitoses, a 
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prevalência de reações a AINEs decorrentes da ativação de mastócitos ronda os 14%, 
nos adultos, e 2% nas crianças (16). Contudo, neste grupo de doenças, estes 
fármacos são os fatores despoletadores de 8% (17) a 11% (18) das crises anafiláticas. 
Assim, a prescrição de AINEs deve ser cautelosa, razão pela qual o seu uso é, 
frequentemente, evitado nas mastocitoses. 
 As reações alérgicas e pseudoalérgicas provocadas por AINEs/fármacos com 
ação inibidora das COX podem ser induzidas por um único fármaco, por um grupo de 
fármacos, ou por fármacos estruturalmente não relacionados (20). As pirazolonas são, 
frequentemente, causa de reações de hipersensibilidade mediada por IgE (20). Porém, 
os restantes fármacos com ação inibidora das COX provocam reações não mediadas 
por IgE – pseudoalérgicas. Estas reações estão, provavelmente, relacionadas com a 
inibição da COX-1, resultante depleção de prostaglandina (PG) E2 e consequente 
libertação de leucotrienos (21, 22). A libertação destes mediadores causa sinais e 
sintomas que podem variar entre sintomas cutâneos leves e choque anafilático (21, 
25). 
 Os doentes que apresentam reações pseudoalérgicas a AINEs podem tolerar 
fármacos inibidores fracos da COX-1 e inibidores seletivos da COX-2 (20, 26). Nas 
mastocitoses, o mecanismo através do qual os AINEs induzem a libertação de 
mediadores mastocitários não é claro, mas poderá ser semelhante ao já descrito. 
 Com este estudo, pretende-se determinar a prevalência de reações provocadas 
pela libertação de mediadores despoletada por AINEs/outros fármacos com ação 
inibidora das COX, mas mastocitoses. Por outro lado, pretende-se descrever achados 
clínicos e laboratoriais, mais frequentemente, associados com estas reações. 
 
 
 
Material e Métodos 
 
 Neste estudo retrospetivo, foram incluídos 417 adultos e 137 doentes 
pediátricos com mastocitose, seguidos pela Red Española de Mastocitosis (REMA), 
até Outubro de 2014. As variáveis em estudo foram:  
1) epidemiológicas: género e idade; 
2) clínicas: tipo de mastocitose, idade de aparecimento da doença, presença de 
atopia, alergias alimentares, asma, rinoconjuntivite, dermatite atópica, alergia a 
veneno de Himenópteros, sintomatologia basal (prurido, flushing e 
sintomatologia gastrointestinal), tolerância e sintomas despoletados por AINEs 
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e outros fármacos com ação inibidora das COX, história de reações 
anafiláticas; 
3) laboratoriais: triptase sérica basal, IgE sérica total, IgE específica, presença de 
mutação do KIT com envolvimento de várias linhagens celulares, carga 
mastocitária da medula óssea;  
4) medicina nuclear/radiológicas: presença de osteosclerose difusa.  
 
 As reações alérgicas/pseudoalérgicas foram avaliadas para cada doente. Esta 
avaliação incluiu a anamnese da reação, seguida de testes cutâneos, na suspeita de 
reações mediadas por IgE, ou de testes de provocação. Nas situações em que o nexo 
de causalidade era baixo, ou em que os sintomas eram leves, foi usado o fármaco, 
potencialmente, responsável pela reação. Nas restantes foram usados outros 
fármacos, com maior potencial de tolerância. Os doentes que apresentaram reações 
provocadas por, pelo menos, dois AINEs/inibidores das COX foram classificados como 
intolerantes a AINEs. Aqueles que não apresentaram reações foram considerados 
como tolerantes a AINEs. Por fim, os doentes que apresentaram reações provocadas 
por apenas um fármaco foram agrupados em 2 grupos: o grupo 1, que incluiu doentes 
que apresentaram reações a um fármaco, tolerando outros fármacos, e o grupo 2, que 
incluiu doentes que reagiram a um fármaco e que nunca mais tomaram outros AINEs. 
Os doentes que nunca tomaram AINEs, ou outros fármacos com ação inibidora das 
COX, à exceção do paracetamol, foram excluídos da análise estatística. 
 
 
Análise Estatística 
   
  Para as variáveis contínuas, foram determinadas a mediana e a amplitude total. 
No caso das variáveis categóricas foram determinas as frequências. A presença de 
diferenças estatisticamente significativas entre os grupos, foi avaliada através dos 
testes de Kruskall Wallis ou U de Mann-Whitney, e do 2 ou teste de coeficientes, 
respetivamente, entre grupos de variáveis contínuas e categóricas. Os valores de corte 
e os respetivos valores preditivos, para os níveis de triptase sérica basal e da carga 
mastocitária da medula óssea foram determinados através de curvas ROC. Os valores 
de p<0.05 foram considerados estatisticamente significativos. A análise estatística dos 
dados colhidos durante estudo foi realizada através do IBM SPSS para Windows, 
versão 23.0, e do Microsoft Excel 2010. 
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Resultados 
 
Doentes adultos 
 
Foram incluídos 417 adultos com mastocitose, 221 (53%) dos quais eram 
mulheres e 196 (47%) eram homens. Dez doentes (2%) tinham mastocitose cutânea 
(CM), 27 (7%) tinham mastocitose na pele (MIS), 207 (50%) tinham mastocitose 
sistémica indolente com lesões cutâneas (ISMs+), 126 (30%) tinham mastocitose 
sistémica indolente sem lesões cutâneas (ISMs-) (7), 18 (4%) tinham mastocitose 
sistémica bem-diferenciada (WDSM) (6), 13 (3%) tinham mastocitose sistémica 
agressiva (ASM), 2 (0.5%) tinham leucemia de mastócitos (MCL) e 8 (2%) tinham 
ISMs+ associada a hemopatia clonal não relacionada com a linhagem mastocitária 
(AHNMD).  
 Verificou-se a presença de atopia em 40% dos doentes, prurido em 52%, 
flushing em 43%, e sintomas gastrointestinais em 37%. Adicionalmente, 46% dos 
doentes apresentavam história de anafilaxia.  
 Trezentos e vinte e nove doentes (79%) toleravam AINEs, 20 (5%) eram 
intolerantes (NSAIDI), 16 (4%) estavam incluídos no grupo 1 e 13 (3%) pertenciam ao 
grupo 2. Os 40 doentes restantes nunca tomaram AINEs, ou outros fármacos com 
ação inibidora das COX, com a excepção do paracetamol. À exceção de 4 doentes 
intolerantes a AINEs, verificou-se que todos os doentes toleravam o paracetamol.  
 Os padrões de tolerância a inibidores das COX, de acordo com o tipo de 
mastocitose estão presentes na tabela III. Verificou-se que estas reações são mais 
frequentes na ASM. A tabela IV explicita a frequência de sintomas basais nos 
diferentes grupos. A tabela V contém as frequências de episódios provocados por cada 
um dos fármacos, em cada um dos grupos. Na tabela VI, podem ser observadas as 
frequências de cada sinal, ou sintoma associado a reações de libertação de 
mediadores mastocitários, causadas por fármacos com ação inibidora das COX. Não 
foram encontradas diferenças estatisticamente significativas entre os grupos.  
 A tabela VIII apresenta as variáveis epidemiológicas, clínicas e laboratoriais, 
em relação a cada um dos grupos. 
 O grupo de doentes intolerantes a AINEs apresentou valores de triptase basal 
sérica superiores (p=0.001), assim como maior carga mastocitária na medula óssea 
(p=0.013); e maiores frequências de mutação do KIT com envolvimento de múltiplas 
28 
 
linhagens e da presença de osteosclerose difusa (respetivamente, p=0.002 e 
p<0.001).  
 A análise com curvas ROC permitiu aferir que níveis de triptase sérica basal 
superiores a 48 ng/mL e uma carga mastocitária na medula óssea superior a 0.12% 
permitem prever a intolerância a AINEs, nos adultos com mastocitose (figuras 1 e 2). 
Adicionalmente, a presença de ambos está associada à presença de envolvimento de 
múltiplas linhagens (p=0.001 e p=0.002, respectivamente) e, ou de osteosclerose 
difusa (p<0.001 e p=0.002, respectivamente). 
Foram realizados testes de provocação com coxibes e, ou meloxicam em 51 
doentes, dos quais: 14 pertenciam ao grupo dos intolerantes, 5 ao grupo 1, 9 ao grupo 
de tolerantes, 7 ao grupo 2 e 16 ao grupo de doentes que nunca tomaram fármacos 
com ação inibidora das COX, à exceção do paracetamol. Os testes foram 
considerados positivos em 3 doentes (6%). Todos pertenciam ao grupo dos 
intolerantes.  
  
 
Doentes pediátricos 
  
 Foram incluídas 137 crianças, 49% das quais do género feminino e 51% do 
género masculino. Destes, 13 (10%) apresentavam mastocitoma cutâneo solitário 
(cM), 5 (4%) tinham mastocitoses sistémicas bem-diferenciadas (WDSM), e os 
restantes 118 (86%) tinham MIS. No que concerne à frequência dos diferentes tipos de 
lesões cutâneas: 87 (64%) doentes apresentavam uma forma maculopapular (MPCM), 
19 (14%) tinham nódulos, 10 (7%) tinham placas (PCM), e 8 (6%) tinham uma 
mastocitose cutânea difusa (DCM). No que diz respeito à sintomatologia basal: 68 
(50%) crianças referiam prurido, 52 (38%) apresentavam episódios de flushing, e 40 
(29%) apresentavam sintomatologia GI. Acresce que 7 (5%) tinham história de reações 
anafiláticas. Os valores de triptase sérica basal variaram entre 1.1 e 149 ng/dL, com 
uma mediana de 5.3 ng/dL.   
 Um total de 120 doentes já tinha tomado paracetamol, sendo que nenhum 
destes apresentou qualquer tipo de reação mediada por mastócitos. Oitenta e sete 
doentes já tinham tomado AINEs ou outros analgésicos/antipiréticos, como o 
ibuprofeno, o metamizol e o ácido acetilsalicílico. 
 Ocorreram reações em apenas 8 doentes (9%), das quais 7 foram provocadas 
por ibuprofeno e 1 foi causada por metamizol. Não foram encontradas diferenças 
estatisticamente significativas entre os grupos definidos pelo padrão de tolerância a 
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AINEs/fármacos com ação inibidora das COX, para as diferentes variáveis estudadas 
(Tabela IX).  
 Foram efetuados testes de provocação em 21 doentes. Administrou-se 
ibuprofeno a 18, celecoxibe a 2 e metamizol a 2 doentes. Todos os testes foram 
negativos.  
 
 
 
Discussão 
  
 Neste estudo, ficou demonstrado que os doentes com mastocitose são mais 
propensos à intolerância a AINEs do que a população geral, apesar de serem seguros 
na esmagadora maioria dos doentes.  
  O risco de reações de libertação de mediadores mastocitários induzidas por 
fármacos com ação inibidora das COX, não é tão alto como se considerava, 
anteriormente. Ainda assim, estas reações traduziram-se em reações anafiláticas em 
8% dos adultos, o que representa 16% dos fatores despoletadores para as reações 
anafiláticas.  
 Verificou-se que os doentes adultos com reações anafiláticas provocadas por 
picadas de Himenópteros são menos propensos a intolerância a AINEs. De facto, 97% 
dos doentes com reações anafiláticas secundárias a picadas de Himenópteros 
toleraram AINEs. Em estudos anteriores, verificou-se que estes doentes são 
habitualmente homens, menos sintomáticos, não apresentam mutação do KIT em 
várias linhagens e apresentam uma baixa carga mastocitária na medula óssea (3). Os 
doentes intolerantes a AINEs apresentam características opostas. 
 Tal como se verifica na população em geral (35), os derivados do ácido 
propiónico foram os AINEs mais frequentemente associados a reações mediadas por 
mastócitos. Não obstante, a prevalência de intolerância a pirazolonas encontrada é 
consideravelmente alta. Estes fármacos foram, aliás, os mais frequentemente 
associados ao grupo 1. Porém, apesar do seu reduzido efeito inibitório sobre a COX-1 
(36, 37), verificou-se que estes fármacos estão frequentemente associados a 
intolerância a AINEs. Na população em geral, a hipersensibilidade a pirazolonas foi 
associada à expressão de HLA-DQ e HLA-DR, previamente descrita nas ISM, ASM e 
MCL (33, 38). Assim, a intolerância ao metamizol e restantes pirazolonas, nos doentes 
com mastocitose, pode ser multifatorial e mais complexa do que previamente se 
pensava. 
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 Na população em geral, demonstrou-se que as reações de hipersensibilidade a 
AINEs podem não estar associadas a altos níveis séricos basais de triptase (39). 
Nesta série, ficou demonstrado que níveis superiores a 48 ng/mL, assim como uma 
carga mastocitária superior a 0,12% podem constituir-se como marcadores associados 
à intolerância a AINEs, em doentes com mastocitose. Verificou-se, também, que a 
presença de níveis séricos basais elevados de triptase, carga mastocitária elevada, 
mutação do KIT com envolvimento de várias linhagens e de osteosclerose difusa estão 
associadas a formas agressivas de mastocitose (40, 41). Assim, as formas não-
indolentes podem apresentar um maior risco de reações provocadas por AINEs. Por 
outro lado, os doentes com CM ou WDSM, sem a mutação D816V do KIT parecem ser 
menos propensos à intolerância a AINEs. Estes resultados podem ser explicados pelo 
facto de que o aumento da transcrição de fatores envolvidos no metabolismo do ácido 
araquidónico, ocorre nas ASM e ISM, podendo estar ausente em doentes sem a 
referida mutação (42). 
  Neste estudo, verificou-se que as reações provocadas por paracetamol ou 
coxibes foram infrequentes nos adultos e não ocorreram em crianças, tal como 
acontece em doentes sem mastocitose, com intolerância a AINEs (20, 26).  
 Este estudo apresenta algumas limitações, nomeadamente no que diz respeito 
à falta de evidência de que as reações reportadas tenham sido, efetivamente, 
provocadas pelos fármacos em estudo. Esta limitação deve-se ao facto de que não 
foram realizados testes de provocação com os fármacos potencialmente indutores das 
referidas reações.  
A percentagem de doentes com mastocitose que nunca tomou AINEs é muito 
elevada. Este facto pode influenciar, seriamente, a qualidade de vida dos doentes, e o 
controlo da dor pode tornar-se uma fonte de ansiedade para os doentes e profissionais 
de saúde. De acordo com os nossos resultados, as reações de libertação de 
mediadores mastocitários provocadas por AINEs não são tão frequentes como se 
considerava, anteriormente. Os doentes que necessitam de tomar AINEs e que nunca 
o fizeram devem ser submetidos a testes de provocação com fármacos com perfil de 
segurança favorável – coxibes e meloxicam, nos adultos, e ibuprofeno nas crianças. 
Os doentes que toleraram AINEs após a data de instalação da mastocitose, não 
requerem investigação, sendo que podem tomar o(s) fármaco(s) que toleraram 
previamente (43). 
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Conclusão 
 
 Tendo por base os resultados deste estudo retrospetivo, pode dizer-se que as 
reações alérgicas/pseudoalérgicas provocadas por AINEs são mais frequentes nas 
mastocitoses, do que na população em geral. Não foram reportados desfechos 
dramáticos do ponto de vista clínico, ou mortes. Assim, as mastocitoses não devem 
ser consideradas contraindicações para a administração de AINEs ou de outros 
fármacos com ação inibidora das COX. Não obstante, a utilização de fármacos com 
perfil de segurança mais favorável é altamente recomendada. Preferencialmente, os 
doentes adultos devem tomar coxibes, meloxicam ou paracetamol. Nos casos em que 
se desconheça se o doente tolera ou não estes fármacos, devem ser realizados testes 
de provocação.  
 A intolerância a AINEs pode estar associada a formas agressivas ou em 
progressão, logo a escolha do AINE deve ser particularmente cuidadosa, nestes 
casos.  
 Deste estudo resulta que valores séricos basais de triptase superiores a 48 
ng/mL e uma carga mastocitária superior a 0,12% podem constituir-se como potenciais 
marcadores, com valor preditivo no que diz respeito à intolerância a AINEs. Porém são 
necessários mais estudos para validar o uso destes marcadores por rotina. 
 
